(Q50559801)

15 March 2018

title

Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C. (English)

1 reference

15 March 2018

1 reference

1 reference

Ajit Sood

1

1 reference

15 March 2018

Praveen Sobti

2

1 reference

15 March 2018

Vandana Midha

3

1 reference

15 March 2018

Dinesh Singla

4

1 reference

15 March 2018

Amarjeet Kaur

5

1 reference

15 March 2018

Sandeep Kaushal

6

1 reference

15 March 2018

Neena Sood

7

1 reference

15 March 2018

Rasham Mittal

8

1 reference

15 March 2018

Sandeep Puri

9

1 reference

15 March 2018

language of work or name

English

0 references

publication date

1 March 2010

1 reference

15 March 2018

Indian Journal of Gastroenterology

published in

1 reference

15 March 2018

volume

29

1 reference

15 March 2018

issue

2

1 reference

15 March 2018

page(s)

62-65

1 reference

15 March 2018

Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12664-010-0014-3

Seroprevalence of hepatitis C and B virus in multiply transfused beta-thalassemics: results from a thalassemic day care unit in north India

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-010-0014-3

Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-010-0014-3

Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-010-0014-3

Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-010-0014-3

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-010-0014-3

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-010-0014-3

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-010-0014-3

Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-010-0014-3

Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-010-0014-3

Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-010-0014-3

Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-010-0014-3

Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-010-0014-3

De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12664-010-0014-3

Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine

21 January 2018

1 reference

12 December 2020

Antibodies to hepatitis C virus in thalassemia

1 reference

12 December 2020

Antibody to hepatitis-C virus in multi-transfused thalassaemics--Indian experience.

1 reference

12 December 2020

Prevalence of hepatitis viruses among multi-transfused homogenous thalassaemia patients

1 reference

12 December 2020

Survival and causes of death in thalassaemia major

1 reference

12 December 2020

10.1007/S12664-010-0014-3

Identifiers

DOI

1 reference

15 March 2018

1 reference

15 March 2018